Lymphoid Leukemia

Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL

Integrated Actionable Aging Assessment for Cancer Patients Pilot

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery

Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation

Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia